When multiple myeloma relapses

RESPOND with the power of Kyprolis®-based regimen (KRd)

KRdKd

KRd progression-free survival

ASPIRE:

The primary endpoint of the trial was PFS, with the results being 26.3 months median PFS with KRd vs 17.6 months with Rd.1

Adding Kyprolis® to the treatment regimen Rd resulted in a significant increase in PFS vs Rd alone – increasing patients’ time without disease progression.1

The use of KRd led to a 1-year improvement in median PFS vs Rd after first relapse (29.6 months with KRd vs 17.6 months with Rd; descriptive P=0.008). 2

Kyprolis® has a tolerable safety profile in combination with Rd Detailed treatment regimen in the KRd pivotal phase 3 ASPIRE study

Aim for similar efficacy in the relapsed setting with KRd compared to 1st line studies in multiple myeloma3,4

*Treatment with the KRd regimen for longer than 18 cycles should be based on an individual benefit–risk assessment (limited data on the tolerability/toxicity of Kyprolis® beyond 18 cycles).5

Please read the SmPC for full comprehensive safety information

References

  1. Stewart AK et al. N Engl J Med 2015;372:142–152.
  2. Dimopoulos MA et al. Presented at the 20th Congress of EHA; 11–14 June 2015; Vienna, Austria. Abstract S427.
  3. San Miguel JF et al. N Engl J Med 2008;359:906–917.
  4. Benboubker L et al. N Engl J Med 2014;371:906–917.
  5. Kyprolis® (carfilzomib) Summary of Product Characteristics; 2016.

Terms of Use

The information contained in this site is for European healthcare professionals only.

Kyprolis